| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Alector Inc. | AL001 | Amyotrophic lateral sclerosis (ALS) | Phase 2 | Ongoing | oral | Neurology |
| Alector Inc. | AL101/GSK4527226 - (PROGRESS-AD) | Early Alzheimer's disease (AD) | Phase 2 | Ongoing | Oral | Neurology |
| Alector Inc. | AL002 - (INVOKE-2) | Alzheimer’s disease | Phase 2 | Data Released | Intravenous | Neurology |
| Alector Inc. | Latozinemab (AL001) - (INFRONT-3) | Frontotemporal Dementia | Phase 3 | Trial Discontinued | intravenous | Neurology |
| Alector Inc. | AL001 - (INFRONT-2) | Frontotemporal Dementia | Phase 2 | Ongoing | Intravenous | Neurology |
| Alector Inc. | Latozinemab (AL001) - (INFRONT-3) | Frontotemporal Dementia | Phase 3 | Trial Discontinued | intravenous | Neurology |
| Aligos Therapeutics Inc. | Pevifoscorvir (ALG-000184) - (B-SUPREME) | Chronic HBV Infection | Phase 2 | Enrollment Initiation | Oral | Antiviral |
| Aligos Therapeutics Inc. | ALG-055009 - (HERALD) | Metabolic dysfunction-associated steatohepatitis (MASH) | Phase 2a | Data Released | Oral | Gastroenterology |